DDInter44 DDInter1008
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Alfuzosin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Terazosin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) resembles {v} (Compound) Prazosin
Prazosin {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Terazosin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) covaries with {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Alfuzosin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Ketoconazole (Compound)
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Alfuzosin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Alfuzosin (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)
Alfuzosin (Compound) resembles Terazosin (Compound) and Terazosin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ketoconazole (Compound)
Alfuzosin (Compound) resembles Prazosin (Compound) and Prazosin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Ketoconazole (Compound)
Alfuzosin (Compound) resembles Terazosin (Compound) and Terazosin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ketoconazole (Compound)
Alfuzosin (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) covaries with CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ketoconazole (Compound)